Target Name: SNORD116-22
NCBI ID: G100033433
Review Report on SNORD116-22 Target / Biomarker Content of Review Report on SNORD116-22 Target / Biomarker
Other Name(s): HBII-85-22 | Small nucleolar RNA, C/D box 116-22 | small nucleolar RNA, C/D box 116-22

Understanding SNORD116-22: A Promising Disease Biomarker and Drug Target

SNORD116-22 is an intriguing and emerging field of research that has captured the attention of scientists and medical professionals worldwide. This specific small nucleolar RNA (snoRNA) holds tremendous potential as both a disease biomarker and drug target. In this article, we will delve into the significance of SNORD116-22, exploring its role in various diseases and the implications for precision medicine.

The Discovery of SNORD116-22

SNORD116-22 was first identified through extensive genome-wide studies and subsequent research efforts in the field of non-coding RNA biology. Located within the 15q11.2 chromosomal region, SNORD116-22 belongs to the SNORD116 cluster, which consists of multiple small nucleolar RNAs.

Although the exact function of SNORD116-22 is yet to be fully elucidated, studies have established a link between this snoRNA and several diseases, highlighting its potential as a critical biomarker and a promising therapeutic target.

SNORD116-22 in Disease

1. Neurodevelopmental Disorders: Neurodevelopmental disorders, such as Prader-Willi syndrome (PWS) and Angelman syndrome (AS), have long been associated with abnormalities in the 15q11.2 chromosomal region, which includes SNORD116-22. PWS is characterized by severe hunger and obesity, while AS exhibits developmental delays and cognitive impairments.

Research has shown that deletion or dysfunction of SNORD116-22 is linked to the development of these neurodevelopmental disorders. Consequently, further investigations are underway to determine the mechanism by which SNORD116-22 contributes to the pathogenesis of PWS and AS, with the ultimate goal of developing targeted therapeutic interventions.

2. Cancer: SNORD116-22 has emerged as a potential biomarker for various types of cancer, including breast, lung, and ovarian cancer. Dysregulation and aberrant expression of this snoRNA have been observed in cancer cells, suggesting its involvement in tumorigenesis and disease progression.

By studying the expression levels of SNORD116-22 in cancer patients, researchers are investigating the possibility of using this snoRNA as a diagnostic marker for early cancer detection. Additionally, targeting SNORD116-22 may prove to be a novel therapeutic strategy for cancer treatment, potentially inhibiting tumor growth and metastasis.

3. Metabolic Disorders: Recent studies have shed light on the role of SNORD116-22 in metabolic disorders, particularly obesity and type 2 diabetes. SNORD116-22 expression levels have been found to be altered in individuals with these conditions, suggesting a potential involvement in metabolic homeostasis.

Understanding the molecular mechanisms underlying the association between SNORD116-22 and metabolic disorders holds great promise for developing personalized treatments. By targeting SNORD116-22, it may be possible to modulate metabolic pathways and restore metabolic balance in affected individuals.

SNORD116-22 as a Drug Target

The identification of SNORD116-22 as a disease-related snoRNA has opened new avenues for therapeutic interventions. Researchers are exploring various approaches to directly target SNORD116-22, some of which include oligonucleotide-based therapies, RNA interference (RNAi), and genome editing techniques.

Harnessing the power of oligonucleotides, such as antisense oligonucleotides (ASOs), can be a promising strategy to modulate SNORD116-22 expression. ASOs can be designed to specifically bind to the snoRNA and regulate its function or stability, offering immense potential in treating diseases associated with SNORD116-22 dysfunction.

Similarly, RNAi technologies aim to silence the expression of SNORD116-22 by introducing small interfering RNAs (siRNAs) that target and degrade the snoRNA. This approach has shown significant success in various therapeutic applications and may hold promise for treating SNORD116-22-related diseases.

Furthermore, advancements in genome editing technologies, such as CRISPR-Cas9, provide a powerful tool for precise modification of genomic sequences. Researchers are exploring the possibility of using CRISPR-Cas9 to correct or restore the dysregulated expression of SNORD116-22, potentially offering a curative approach for certain diseases.

The Road Ahead: Precision Medicine

The discovery of SNORD116-22 as both a biomarker and drug target has immense implications on the future of precision medicine. By understanding the role of this snoRNA in various diseases, clinicians can develop tailored therapeutic strategies that address the root cause of the condition.

Moreover, the potential use of SNORD116-22 as a diagnostic marker opens doors for early disease detection and intervention. In combination with other clinical indicators, the measurement of SNORD116-22 levels could enhance healthcare professionals' ability to identify individuals at high risk for specific diseases.

As research progresses, it is crucial to continue investigating SNORD116-22's biological function, molecular interactions, and potential therapeutic approaches. Collaborative efforts between researchers, clinicians, and pharmaceutical companies are necessary to expedite the development of novel therapies targeting this fascinating snoRNA.


In conclusion, SNORD116-22 represents an exciting avenue of research that holds immense promise as a disease biomarker and drug target. Understanding its role in neurodevelopmental disorders, cancer, and metabolic disorders provides a foundation for developing personalized diagnostic tools and therapeutic interventions. Continued research in this field will undoubtedly pave the way for precision medicine, revolutionizing the way we approach the prevention and treatment of various diseases.

Protein Name: Small Nucleolar RNA, C/D Box 116-22

The "SNORD116-22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD116-22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

SNORD116-23 | SNORD116-24 | SNORD116-25 | SNORD116-26 | SNORD116-27 | SNORD116-28 | SNORD116-29 | SNORD116-3 | SNORD116-4 | SNORD116-5 | SNORD116-6 | SNORD116-7 | SNORD116-8 | SNORD116-9 | SNORD116@ | SNORD117 | SNORD118 | SNORD119 | SNORD11B | SNORD12 | SNORD121A | SNORD121B | SNORD123 | SNORD124 | SNORD125 | SNORD126 | SNORD12B | SNORD12C | SNORD13 | SNORD139 | SNORD13P2 | SNORD13P3 | SNORD14A | SNORD14B | SNORD14C | SNORD14D | SNORD14E | SNORD15A | SNORD15B | SNORD16 | SNORD17 | SNORD18A | SNORD18C | SNORD19 | SNORD19B | SNORD1A | SNORD1B | SNORD1C | SNORD2 | SNORD20 | SNORD21 | SNORD22 | SNORD23 | SNORD24 | SNORD25 | SNORD26 | SNORD27 | SNORD28 | SNORD29 | SNORD30 | SNORD31 | SNORD32A | SNORD32B | SNORD33 | SNORD34 | SNORD35A | SNORD35B | SNORD36A | SNORD36B | SNORD36C | SNORD37 | SNORD38A | SNORD38B | SNORD3A | SNORD3B-1 | SNORD3B-2 | SNORD3C | SNORD3D | SNORD41 | SNORD42A | SNORD42B | SNORD43 | SNORD44 | SNORD45A | SNORD45B | SNORD46 | SNORD47 | SNORD48 | SNORD49A | SNORD49B | SNORD4A | SNORD4B | SNORD5 | SNORD50A | SNORD50B | SNORD51 | SNORD52 | SNORD53 | SNORD54 | SNORD55